Caroline Seydel

All articles by Caroline Seydel

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.

Triple Therapy for CLL Shows Promise in Phase 2 Trial

By

Caroline Seydel

September 23, 2020

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.

Ten different drugs continued to kill cancer cells even when their target proteins were removed.

General Oncology

Some Targeted Therapies May Miss the Mark

By

Caroline Seydel

October 17, 2019

Ten different drugs continued to kill cancer cells even when their target proteins were removed.

Next post in General Oncology

Increasing healthcare costs

Cost of Waste in U.S. Health System Estimated